Gender-dependent association of TYMS-TSER polymorphism with 5-fluorouracil or capecitabine-based chemotherapy toxicity

Autor:	Vangelis G. Manolopoulos, Charalampia Ioannou, Triantafyllia Koukaki, Nikolaos Xenidis, Ioanna Balgkouranidou, Stylianos Kakolyris, Eirini Biziota, Georgia Ragia, K. Amarantidis
Rok vydání:	2021
Předmět:	Pharmacology Oncology medicine.medical_specialty business.industry Cancer Odds ratio medicine.disease Capecitabine Fluorouracil Polymorphism (computer science) Internal medicine Pharmacogenomics Genotype Genetics medicine Molecular Medicine Adverse effect business medicine.drug
Zdroj:	Pharmacogenomics. 22:669-680
ISSN:	1744-8042 1462-2416
DOI:	10.2217/pgs-2021-0031
Popis:	Aim: TYMS gene encodes for TS enzyme involved in 5-fluorouracil (5-FU) and capecitabine (CAP) metabolism. This study assessed the association of TYMS-TSER and 3RG>C polymorphisms with 5-FU/CAP adverse event (AE) incidence. Materials & methods: TYMS-TSER and 3RG>C polymorphisms were analyzed by use of PCR/PCR-RFLP in 313 5-FU/CAP-treated cancer patients. Results: Female TYMS-TSER 2R carriers were at increased risk for 5-FU/CAP AEs (odds ratio: 2.195; p = 0.032). 2R/2R genotype was the only factor that increased risk for delayed drug administration or therapy discontinuation (odds ratio: 5.049; p = 0.016). No other associations were found. Conclusion: TYMS-TSER 3R/2R polymorphism was associated with incidence of AEs in female cancer patients. This gender-driven association potentially implicates the ER that, in female patients, potentially regulates TS expression.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::41bc79885e915ff100570c2f8f8f2487 https://doi.org/10.2217/pgs-2021-0031 Zobrazit plný text záznamu